Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term 80 and over Aged. Found 232 abstracts

no pagination
Margulis V, Puligandla M, Trabulsi EJ, Plimack ER, Kessler ER, Matin SF, Godoy G, Alva A, Hahn NM, Carducci MA, Hoffman-Censits J. Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma. J Urol. 2020 Apr;203(4):690-8.
Qian L, Soderquist C, Schrank-Hacker A, Strauser H, Dupoux V, Tang CN, Smith JR, Sun A, Majumdar S, Nguyen T, Widura S, Landsburg DJ, Schuster SJ, Baxter RH, Bogusz AM. Deletion 20q12 is associated with histological transformation of nodal marginal zone lymphoma to diffuse large B-cell lymphoma. American journal of hematology. 2020 Mar;95(3):238-44.
Churilla TM, Chowdhury IH, Handorf E, Collette L, Collette S, Dong Y, Alexander BM, Kocher M, Soffietti R, Claus EB, Weiss SE. Comparison of Local Control of Brain Metastases With Stereotactic Radiosurgery vs Surgical Resection: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2019 Feb;5(2):243-7.   PMCID: PMC6439566
Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algul H, O'Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. The New England journal of medicine. 2019 Jul 25;381(4):317-27.   PMCID: PMC6810605
Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O'Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. The New England journal of medicine. 2019 Sep 28;381(21):2020-31.
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulieres D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2019 Mar 21;380(12):1116-27.
Bartel MJ, Puri R, Brahmbhatt B, Chen WC, Kim D, Simons-Linares CR, Stauffer JA, Buchanan MA, Bowers SP, Woodward TA, Wallace MB, Raimondo M, Asbun HJ. Endoscopic and surgical management of nonampullary duodenal neoplasms. Surgical endoscopy. 2018 Jun;32(6):2859-69.
Gettinger S, Hellmann MD, Chow LQ, Borghaei H, Antonia S, Brahmer JR, Goldman JW, Gerber DE, Juergens RA, Shepherd FA, Laurie SA, Young TC, Li X, Geese WJ, Rizvi N. Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC. J Thorac Oncol. 2018 Sep;13(9):1363-72.
Geynisman DM, Meeker CR, Doyle JL, Handorf EA, Bilusic M, Plimack ER, Wong YN. Provider and patient burdens of obtaining oral anticancer medications. The American journal of managed care. 2018 Apr;24(4):e128-e133.
Harshman LC, Chen YH, Liu G, Carducci MA, Jarrard D, Dreicer R, Hahn N, Garcia JA, Hussain M, Shevrin D, Eisenberger M, Kohli M, Plimack ER, Cooney M, Vogelzang NJ, Picus J, Dipaola R, Sweeney CJ. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol. 2018 Feb;36(4):376-82.   PMCID: PMC5805480
Jackson WC, Dess RT, Litzenberg DW, Li P, Schipper M, Rosenthal SA, Chang GC, Horwitz EM, Price RA, Michalski JM, Gay HA, Wei JT, Feng M, Feng FY, Sandler HM, Wallace RE, Spratt DE, Hamstra DA. A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life. Practical radiation oncology. 2018 Jan;8(1):40-7.
Jones RL, Demetri GD, Schuetze SM, Milhem M, Elias A, Van Tine BA, Hamm J, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Patel S, von Mehren M. Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Ann Oncol. 2018 Sep;29(9):1995-2002.   PMCID: PMC6454486
Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Stephenson AJ, Klein EA, Song DY, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco S, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. Jama. 2018 Mar 06;319(9):896-905.   PMCID: PMC5885899
Lamb EP, Pritchard FE, Nouer SS, Tolley EA, Boyd BS, Davidson JT, Munene G, Fleming MD. Understanding Disparities in Breast Cancer Care in Memphis, Tennessee. Am Surg. 2018 May;84(5):620-7.
Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Geva R, Chung HC, Lin CC, Aurora-Garg D, Ray A, Pathiraja K, Cheng J, Chow LQ, Haddad R. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer. 2018 Jul;119(2):153-9.   PMCID: PMC6048158
Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthelemy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2018 Apr 05;378(14):1277-90.   PMCID: PMC5972549
Shaikh T, Wang LS, Egleston B, Burki M, Hoffman JP, Cohen SJ, Meyer JE. Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer. Am J Clin Oncol. 2018 Jan;41(1):59-64.   PMCID: PMC4769977
Arthur DW, Winter KA, Kuerer HM, Haffty BG, Cuttino LW, Todor DA, Simone NL, Hayes SB, Woodward WA, McCormick B, Cohen RJ, Sahijdak WM, Canaday DJ, Brown DR, Currey AD, Fisher CM, Jagsi R, White J. NRG Oncology-Radiation Therapy Oncology Group Study 1014: 1-Year Toxicity Report From a Phase 2 Study of Repeat Breast-Preserving Surgery and 3-Dimensional Conformal Partial-Breast Reirradiation for In-Breast Recurrence. Int J Radiat Oncol Biol Phys. 2017 Aug;98(5):1028-35.   PMCID: PMC5572128
Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 Nov;18(11):1483-92.
Bhimla A, Yap L, Lee M, Seals B, Aczon H, Ma GX. Addressing the Health Needs of High-Risk Filipino Americans in the Greater Philadelphia Region. J Community Health. 2017 Apr;42(2):269-77.   PMCID: PMC5337442
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term 80 and over Aged

80 and over Aged Aged Middle Aged Male Adult Female pathology mortality adverse effects drug therapy therapeutic use administration & dosage Retrospective Studies Survival Analysis Antineoplastic Combined Chemotherapy Protocols methods Local Neoplasm Recurrence Disease-Free Survival Drug Administration Schedule therapy Prostatic Neoplasms Young Adult Progression-Free Survival Kidney Neoplasms Neoplasm Metastasis Kaplan-Meier Estimate Time Factors surgery Neoplasm Staging genetics statistics & numerical data Monoclonal Antibodies-Humanized Adolescent Antineoplastic Agents Prospective Studies Follow-Up Studies Treatment Outcome Single-Blind Method Neoplasm Invasiveness secondary Immunological Antineoplastic Agents drug effects Disease Progression Survival Rate Neoplastic Gene Expression Regulation Lung Neoplasms metabolism Transitional Cell Carcinoma Breast Neoplasms Prognosis Renal Cell Carcinoma Nivolumab ethnology Radiosurgery Androgen Antagonists radiotherapy Non-Small-Cell Lung Carcinoma Intravenous Administration Health Services Accessibility Radiation Injuries Pancreatic Neoplasms B7-H1 Antigen Ipilimumab Quality of Life Drug Dose-Response Relationship Risk Assessment Neoplasm Grading Intraductal Carcinoma-Noninfiltrating Nonampullary duodenal neoplasms Chemoradiotherapy epidemiology Age Factors Programmed death 1 axis inhibitor Exercise Nephroureterectomy blood Maintenance Chemotherapy Community health Dietary behaviors Cisplatin Trabectedin Tennessee Duodenal Neoplasms Carcinoma Piperazines Pharmaceutical Services Insurance Dacarbazine Incidence Prostatectomy urinary tract Diet Length of Stay Registries Pyrroles Randomized Controlled Trials as Topic Urothelium Fibrosis Endoscopic Mucosal Resection Intensity-Modulated Radiotherapy etiology Radiation Oncology biosynthesis adverse Ureteral Neoplasms Health Status Disparities Brain Neoplasms physiopathology Adenocarcinoma Oral Administration Radiotherapy Double-Blind Method Phthalazines Health Services Needs and Demand Reoperation effects European Continental Ancestry Group Predictive Value of Tests Internationality African Americans radiation effects BRCA2 Genes Large B-Cell Lymphoma-Diffuse Alkylating Antineoplastic Agents Postoperative Complications urothelium BRCA1 Genes diagnosis Surgical Blood Loss Liposarcoma Hematologic Diseases Emigrants and Immigrants Endoscopic resection Re-Irradiation Philadelphia Germ-Line Mutation Neoplasm Proteins Risk Factors Chromosome Deletion Neurosurgical Procedures pharmacology carcinoma Conformal Radiotherapy Operative Time Erlotinib Hydrochloride Prostate-Specific Antigen Deductibles and Coinsurance Hormone-Dependent Neoplasms Erlotinib Programmed Cell Death 1 Receptor EGFR-mutant NSCLC
Last updated on Saturday, July 04, 2020